Prospects for a better vaccine against tuberculosis

Tuberculosis

Volumn 83, Issue 1-3, 2003, Pages 213-219

  Reed, S G ^a,b   Alderson, M R ^a   Dalemans, W ^c   Lobet, Y ^c   Skeiky, Y A W ^a  

^a GLAXOSMITHKLINE   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; VACCINE;

BACTERIAL GENOME; CELLULAR IMMUNITY; CONFERENCE PAPER; FINANCIAL MANAGEMENT; GENE DELIVERY SYSTEM; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; IMMUNITY; INFECTION RESISTANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUBERCULOSIS;

EID: 0038180875     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(02)00080-X     Document Type: Conference Paper

References (23)

1. Van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000;30:3689-98.
2. Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989;11(2):S353-9.
3. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002;70:672-8.
4. Sambandamurthy VK, Wang X, Chen B, et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 2002;8:1171-4.
5. Coler RN, Campos-Neto A, Ovendale P, et al. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol 2001;166:6227-35.
6. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2:893-8.
7. Baldwin SL, D'Souza CD, Orme IM, et al. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuber Lung Dis 1999;79:251-9.
8. Ulmer JB, Deck RR, DeWitt CM, et al. Induction of immunity by DNA vaccination: application to influenza and tuberculosis. Behring Inst Mitt 1997;98:79-86.
9. Skeiky YAW, Ovendale PJ, Jen S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 2000;165:7140-9.
10. Dillon D, Alderson MR, Day CH, et al. Molecular characterization and human T cell responses to a member of a novel Mycobacterium tuberculosis Mtb39 gene family. Infect Immun 1999;67:2941-50.
11. Morris S, Kelley C, Howard A, Li Z, Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000;18:2155-63.
12. Lowrie DB, Tascon RE, Bonato VL, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999;400:269-71.
13. Tanghe A, Lefevre P, Denis O, et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999;162:1113-9.
14. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000;68:791-5.
15. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999;67:1702-7.
16. Fonseca DP, Benaissa-Trouw B, van Engelen M, Kraaijeveld CA, Snippe H, Verheul AF. Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein. Infect Immun 2001;69:4839-45.
17. Baldwin SL, D'Souza C, Roberts AD, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998;66:2951-9.
18. Olsen AW, Pinxteren LAH, Okkels LM, Rasmussen P B, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and ESAT-6. Infect Immun 2001;69:2773-8.
19. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97:13853-8.
20. McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol Med 2001;7:135-7.
21. Walsh GP, Tan EV, Dela Cruz EC, et al. The Philippine cynomolsus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996;2:430-6.
22. Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999;19:103-7.
23. Baldridge JR, Ward JR. Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity. Vaccine, 1997;15:395-401.